

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

Claims 1-31 (canceled).

32. (currently amended) A compound capable of specific interaction with parkin, wherein the compound is a peptide ~~comprising~~ having an amino acid sequence of at least 95% identity to the full length PAP1 sequence of SEQ ID NO: 2 ~~all or part of the amino acid sequence of SEQ ID NO: 2.~~

33. (previously presented) A compound as claimed in claim 32, which inhibits the interaction between PAP1 and parkin.

Claims 34-37 (canceled).

38. (currently amended) A compound as claimed in claim 32, which is a peptide compound containing an effector region, where the effector region ~~that~~ has been rendered nonfunctional.

39. (currently amended) An isolated peptide or polypeptide comprising the amino acid sequence of ~~one of~~ SEQ ID NO. 2, 13, 15, 43, or 45, ~~or fragment thereof.~~

Claims 40-52 (canceled).

53. (previously presented) A composition comprising a compound as claimed in claim 32 and a pharmaceutically acceptable vehicle or excipient.

Claims 54-58 (canceled).

59. (previously presented) A composition comprising a compound as claimed in claim 32, and a carrier.

Claims 60-62 (canceled).

63. (new) A composition comprising a compound as claimed in claim 32, wherein the PAP1 sequence of SEQ ID NO: 2 includes a Pro at position 148.

64. (new) A composition comprising a compound as claimed in claim 32, wherein the PAP1 sequence of SEQ ID NO: 2 includes a Gln at position 321.

Appl. No. 09/785,548

Response to Notice of Non-Compliant Amendment dated 9/30/04

Notice of Non-Compliant Amendment dated 8/31/04

65. (new) A composition comprising a compound as claimed in claim 66, wherein the PAP1 sequence of SEQ ID NO: 2 includes a Gln at position 321.